GENB vs ZYME: Which Stock Is the Better Buy?
Generate Biomedicines, Inc. and Zymeworks Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — GENB vs ZYME, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Generate Biomedicines, Inc. (GENB) | Zymeworks Inc. (ZYME) | |
|---|---|---|
| Market cap | $1.7B | $1.7B |
| Revenue (latest FY) | $31.89M | $105.97M |
| Net income (latest FY) | $-203.15M | $-81.13M |
| Revenue growth (5y CAGR) | — | 22.2% |
| Net margin | -637.0% | -76.6% |
| Return on equity | 33.0% | -30.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full GENB vs ZYME breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open GENB's full financials → Open ZYME's full financials →More comparisons
Frequently asked questions
Which is bigger, GENB or ZYME?
Zymeworks Inc. is larger by market capitalization — $1.7B versus $1.7B.
Which grows faster, GENB or ZYME?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.